Managing patients on Tildrakizumab
Tildrakizumab (Ilumya), an interleukin-23 (IL-23) inhibitor offers a convenient dosing schedule. Treatment is administered by subcutaneous injection at start of treatment, after 4 weeks, followed by every 12 weeks thereafter. This dosing regimen is generally less frequent compared to other biologic medications, with only 4 injections needed each year for maintenance. A less frequent dosing regimen can offer more convenience and quality of life for patients, which in-turn can improve their satisfaction and adherence to treatment.
